Becton, Dickinson and Company (BDX) said Tuesday it will invest $110 million to establish BD Neopak glass prefillable syringe production at its site in Columbus, Nebraska, with supply expected to begin in mid-2026.
BD Neopak glass prefillable syringe production will be available in 1 mL and 2.25 mL formats, the company said.
A part of the investment will go toward additional line upgrades and capacity improvements at the facility.
BD will also invest $10 million to improve cannula manufacturing capabilities at the site.
BD said these investments are expected to create around 120 new jobs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments